Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

In its first-quarter 2025 investor letter, ClearBridge Large Cap Value Strategy highlighted stocks such as Novo Nordisk A/S (NYSE ... Disruption is the New Name of the Game: Let’s face it ...

Investing.com -- Shares of Novo Nordisk (NYSE ... a CEO transition, without meaningful change in near-term strategy, we continue to see a more difficult path forward for the name." ...

Novo Nordisk (NYSE ... The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped ...

Seigerman said a CEO transition might satisfy some investors, but without a meaningful change in its near-term strategy, the company's path forward seems difficult. DANSKE BANK ANALYST CARSTEN LONBORG ...

Editor’s Note: This story was updated at 9:30 a.m. ET to provide detail from Novo Nordisk’s ... a CEO transition, without meaningful change in near-term strategy, we continue to see a more difficult ...

By Rebecca Robbins Novo Nordisk will replace its chief executive ... In most cases patients who pay out of pocket for the drugs, without using insurance, can get them for $500 a month.